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PCN8
ANTIPSYCHOTIC DRUG USE AND 
HOSPITALISATION IN PATIENTS
WITH SCHIZOPHRENIA
de Vries CS, Boyle DIR, MacDonald TM
Dundee University, Medicines Monitoring Unit, Dundee, Scotland
BACKGROUND: The treatment of schizophrenia with
psychotropic drugs is complicated by side effects and lack
of efficacy. The newer, atypical psychotropic drugs may
have fewer side effects and may reduce the relapses that
lead to hospitalization. We performed a population-based
study of psychotropic use, co-prescription, and hospital-
izations in schizophrenic patients in the Dundee catchment
area of Scotland.
METHODS: All individuals within the population base
who were hospitalized for schizophrenia between January
1980 and October 1995 were identified and followed up
from January 1993 until October 1995. The following
psychotropic drug groups were studied: phenothiazines
(P), thioxanthenes (T), butyrophenones (B), diphenyl butyl
piperidines (D), and atypical psychotropics (A). For these
drug groups, community-based dispensed prescribing was
studied and the following events were recorded: discontin-
uation of psychotropic use, switches to other psychotro-
pics, co-prescribing of other psychotropics, or co-prescrib-
ing for the treatment of side effects. Prescribing adherence
was calculated as the number of patient days of medica-
tion dispensed per 100 patient days. In each drug group,
the incidence of hospitalizations was calculated. Differ-
ences between drug groups were calculated as odds ratios.
RESULTS: 353 schizophrenic patients with sufficient fol-
low-up time were identified. Patients who used phenothi-
azines were at lowest risk of hospitalization (OR 0.1; CI95
0.5–0.14), and switch behavior (OR 0.4; CI95 0.3–0.6).
With phenothiazines as the reference group, odds ratios
for hospitalization varied from 9.2 (B; CI95 4.6–18.4) to
24.0 (D; CI95 8.6–65.0) for the other drug groups; odds ra-
tios for switching varied from 1.7 (B; CI95 0.9–3.0) to 3.7
(A; CI95 1.8–8.0), and odds ratios for co-prescribing varied
from 0.9 (A; CI95 0.6–1.5) to 1.2 (B; CI95 0.7–2.0). Adher-
ence to all drug groups was poor (P: 53%; B: 55%; D:
66%; T: 44%; A: 67%).
DISCUSSION: Hospitalizations, switches, and co-pre-
scribing all were less frequent with phenothiazines than in
any of the other psychotropic drug groups. Phenothiazines
are the drugs of first choice for schizophrenia in the UK,
and these results probably represent channeling of second-
line drugs to those that have failed or had adverse drug re-
actions with phenothiazines. Compliance was poor with
all drug groups and this is a cause for concern as a propor-
tion of treatment failure may be as a result of this.
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COST-EFFECTIVENESS ANALYSIS AND SOCIAL 
ASPECTS OF THE PALMITATE PIPOTIASINE 
OUTPATIENT TREATMENT IN SCHIZOPHRENIA
Gurovich I1, Kobina S2, Litvischenko Y1, Lyubov E1, Shmukler A1
1Moscow Research Institute of Psychiatry of the Russian 
Federation, Moscow, Russia; 2Rhone-Poulence Rorer, Moscow, 
Russia
OBJECTIVES: This study focused on evaluation of cost-
effectiveness in the treatment with palmitate pipotiazine
(Piportil L 4) vs. oral forms of traditional neuroleptics in
public psychiatric outpatient clinic in Moscow.
METHODS: To 25 outpatients with ICD-10 defined diag-
nosis of schizophrenia was prescribed palmitate pipotiazine
for a period of six months in the present “mirror”—image
analysis. Our intention was that the study should interfere
as little as possible with routine clinical practice. Clinical
improvement, drug tolerability and social functioning of
the patients were evaluated with the PANSS, CGI scale,
EPRS scale and original checklist on social functioning and
quality of life (Gurovich & Shmukler, 1998). Economic
evaluation was performed including relevant data about
the direct and indirect costs for all of the patients.
RESULTS: The data obtained indicate some statistically
significant (p  0.05) clinical improvement with the
PANSS, CGI scale as well as reduced drug side effects with
ESRS (p  0.05). The improvement of social functioning
and quality of life was indicated. The treatment of palmi-
tate pipotiazine ensures a reduction of relapses, improving
quality of remission states and a facilitation of the social
adaptation of the patients. So direct and indirect costs were
reduced. The study demonstrates cost-effectiveness of the
treatment with palmitate pipotiazine (especially for the pa-
tients at high risk for future relapse and rehospitalization.)
cf oral forms of conventional antipsychotics.
CONCLUSIONS: It was concluded that the constant and
prolonged outpatient maintenance treatment with palmi-
tate pipotiazine should be cost saving alternative for the
management of outpatients with schizophrenia in “real
world” practice.
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A CROSS-SECTIONAL ANALYSIS OF HEALTH 
CARE COST OF SSRI USERS
Goodman M, DeFor T, Cooper S, Maciosek M
HealthPartners Research Foundation, Bloomington, MN, USA
OBJECTIVES: Many pharmaco-economic studies have
sought to identify the cost-effectiveness of different SSRI
antidepressants. In order to replicate randomized con-
trolled trials, many of these studies have reduced the SSRI-
user population to small, often unrepresentative numbers.
This study seeks to inform health plan decision-makers by
studying a one-year cross-sectional population of SSRI us-
ers. This population-based perspective is useful in under-
standing natural differences in SSRI use.
METHODS: We identified 27,134 SSRI users in 1997 in a
large, mixed model HMO. For each user we identified total
SSRI days, SSRI cost, total pharmacy cost, total health plan
cost using charges, paid amounts, and a standardized cost
algorithm, and comorbidities using the Charlson comorbid-
ity index. Statistical methods appropriate to the highly
